This study is a single centre, prospective, randomized, open labeled clinical study to evaluate the effectiveness of Siddha herbal formulation, Vipro, towards the management of uncomplicated respiratory infection including common cold with / without fever, flu like respiratory infection, bacterial respiratory infection and unidentified SARS-CoV-2-like respiratory infection.

The patients will be enrolled at Chettinad Hospital and Research Institute, Kelambakkam, with prior informed consent.

The subjects will be grouped into three as follows.

Group 1: Standard treatment (symptomatic management with antipyretics and / or antihistamines and / or nasal decongestants and / or antibiotics and / or cough syrups for duration of 3 to 5 days as decided by the treating physician)

Group 2: Liquid, oral, poly herbal formulation ‘Vipro’,  one teaspoon of formulation, mixed in a glass of water, mixed thoroughly and swallowed after food for 7 days, for four times a day, morning, afternoon, evening and night.

             Group 3: Standard Treatment + Vipro combination will be advised as in group 1 and 2

Baseline assessment on day 0:

The patients who fulfill the inclusion and exclusion criteria will be enrolled in the study. They will be allocated to any of the treatment groups as per the randomization.  The following baseline data will be collected.

• Demographic profile - age, gender, height, weight and BMI will be recorded
• Blood pressure, Pulse, SpO2, Respiratory rate, Body temperature and constitutional symptoms 
• General examination, systemic clinical examination
• Complete blood count (with 5 ml of blood drawn) and Throat / Nasal swab for bacterial culture and sensitivity
• Chest X ray and Nasal / Throat swab for COVID - when indicated as per the opinion of the treating physician

After the baseline assessment, the subjects will be provided with any one of the following treatments.

Group 1: Symptomatic management with antipyretics and / or antihistamines and / or nasal decongestants and / or antibiotics and / or cough syrups for duration of 3 to 5 days as decided by the treating physician

Group 2: Liquid, oral, poly herbal formulation ‘Vipro’,  one teaspoon of formulation, mixed in a glass of water, mixed thoroughly and swallowed after food for 7 days, for four times a day, morning, afternoon, evening and night.

Group 3: Combination of both treatments of group 1 and 2

Follow up assessment (days 1 to 7):

Telephonic follow up (days 1 to 7) – Reminder for medication intake (daily once), Adverse events (daily once), Clinical symptoms for improvement / worsening (daily once), body temperature and constitutional symptoms

Physical follow up (On days 4 and 7) – Checking medication compliance, Blood pressure, Pulse, SpO2, Respiratory rate, Body temperature, constitutional symptoms, adverse events, General and Systemic examination, clinical signs and symptoms

During follow up - Complete blood count (with 5 ml of blood drawn) and Throat / Nasal swab for culture and sensitivity on day 7.  Chest X ray and Throat / Nasal swab for COVID - when indicated as per the opinion of the treating physician.

If the subjects are found to deteriorate with the treatments followed, they will be withdrawn from the study and suitable alternate treatment will be provided.